HRP20210909T1 - Kristalni oblici modulatora androgenih receptora - Google Patents
Kristalni oblici modulatora androgenih receptora Download PDFInfo
- Publication number
- HRP20210909T1 HRP20210909T1 HRP20210909TT HRP20210909T HRP20210909T1 HR P20210909 T1 HRP20210909 T1 HR P20210909T1 HR P20210909T T HRP20210909T T HR P20210909TT HR P20210909 T HRP20210909 T HR P20210909T HR P20210909 T1 HRP20210909 T1 HR P20210909T1
- Authority
- HR
- Croatia
- Prior art keywords
- theta
- xrpd
- pattern
- ray powder
- powder diffraction
- Prior art date
Links
- 239000000849 selective androgen receptor modulator Substances 0.000 title 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 36
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 claims 10
- 238000003860 storage Methods 0.000 claims 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 102000001307 androgen receptors Human genes 0.000 claims 3
- 108010080146 androgen receptors Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 2
- 239000006187 pill Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 238000002411 thermogravimetry Methods 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims 1
- 229940011051 isopropyl acetate Drugs 0.000 claims 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000001757 thermogravimetry curve Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (14)
1. Farmaceutski pripravak, naznačen time, da sadrži 4-[7-(6-cijano-5-trifluorometilpiridin-3-il)-8-okso-6-tiokso-5,7-diaza-spiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamid;
pri čemu 4-[7-(6-cijano-5-trifluorometilpiridin-3-il)-8-okso-6-tiokso-5,7-diaza-spiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamid jest kristalni Oblik B;
i pri čemu je kristalni Oblik B naznačen time da posjeduje najmanje jedno od sljedećih:
a) isti uzorak rendgenske difrakcije na prahu (XRPD) kako je prikazan na Slici 2;
b) uzorak rendgenske difrakcije na prahu (XRPD) s karakterističnim vršnim vrijednostima na 12,1+0,1° 2-Theta, 16,0±0,1° 2-Theta, 16,7±0,1° 2-Theta, 20,1±0,1° 2-Theta, 20,3±0,1° 2-Theta;
c) jedinični stanični parametri koji su jednaki sljedećima na -173°C:
[image]
d) isti uzorak rendgenske difrakcije nu praha (XRPD) kao za a) ili b) nakon skladištenja na 40°C i 75% RH u trajanju od najmanje tjedan dana; ili
e) isti uzorak rendgenske difrakcije na prahu (XRPD) kao za a) ili b) nakon skladištenja na 25°C i 92% RH u trajanju od 12 dana.
2. Farmaceutski pripravak prema patentnom zahtjevu 1, naznačen time, da je kristalni oblik naznačen time da posjeduje najmanje jedno od:
f) DSC termogram kao što je prikazan na Slici 11;
g) termogram termo-gravimetrijske analize (TGA) kao što je prikazan na Slici 11; ili
h) DSC termogram s endotermom koji ima početnu temperaturu na 194°C.
3. Farmaceutski pripravak prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time, da kristalni oblik ima uzorak rendgenske difrakcije na prahu (XRPD) s karakterističnim vršnim vrijednostima na 12,1+0,1° 2-Theta, 16,0±0,1° 2-Theta, 16,7±0,1° 2-Theta, 20,1±0,1° 2-Theta, 20,3±0,1° 2-Theta.
4. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da kristalni oblik ima isti uzorak rendgenske difrakcije na prahu (XRPD) kakav je prikazan na Slici 2.
5. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da kristalni oblik ima jedinične stanične parametre jednake sljedećima na -173°C:
[image]
6. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da navedeni farmaceutski pripravak sadrži 0,3 mg do 1,5 g 4-[7-(6-cijano-5-trifluorometilpiridin-3-il)-8-okso-6-tiokso-5,7-diaza-spiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamida po dozi.
7. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da nadalje sadrži farmaceutski prihvatljiv nosač.
8. Postupak, naznačen time, da obuhvaća pripravu kristalnog Oblika B od 4-[7-(6-cijano-5-trifluorometilpiridin-3-il)-8-okso-6-tiokso-5,7-diaza-spiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamida;
pri čemu je kristalni Oblik B naznačen time da posjeduje najmanje jedno od sljedećih:
a) istiuzorak rendgenske difrakcije na prahu (XRPD) kako je prikazan na Slici 2;
b) uzorak rendgenske difrakcije na prahu (XRPD) s karakterističnim vršnim vrijednostima na 12,1±0,1° 2-Theta, 16,0±0,1° 2-Theta, 16,7±0,1° 2-Theta, 20,1±0,1° 2-Theta, 20,3±0,1° 2-Theta;
c) jedinični stanični parametri koji su jednaki sljedećima na -173°C:
[image]
d) isti uzorak rendgenske difrakcije na prahu (XRPD) kao za a) ili b) nakon skladištenja na 40°C i 75% RH u trajanju od najmanje tjedan dana; ili
e) isti uzorak rendgenske difrakcije na prahu (XRPD) kao za a) ili b) nakon skladištenja na 25°C i 92% RH u trajanju od 12 dana,
pri čemu se Oblik B dobiva iz vode, etil acetata, terc-butil metiletera (TBME), toluena, izopropilacetata ili metil etil ketona (MEK).
9. Postupak prema patentnom zahtjevu 8, naznačen time, da obuhvaća pripravu amorfne faze 4-[7-(6-cijano-5-trifluorometilpiridin-3-il)-8-okso-6-tiokso-5,7-diaza-spiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamida.
10. Uporaba 4-[7-(6-cijano-5-trifluorometilpiridin-3-il)-8-okso-6-tiokso-5,7-diaza-spiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamida Oblika B, naznačena time, da je za proizvodnju lijeka za liječenje ili prevenciju bolesti, poremećaja ili stanja povezanog s djelovanjem androgenog receptora;
pri čemu je kristalni Oblik B naznačen time da posjeduje najmanje jedno od sljedećih:
a) istiuzorak rendgenske difrakcije na prahu (XRPD) kako je prikazan na Slici 2;
b) uzorak rendgenske difrakcije na prahu (XRPD) s karakterističnim vršnim vrijednostima na 12,1+0,1° 2-Theta, 16,0±0,1° 2-Theta, 16,7±0,1° 2-Theta, 20,1±0,1° 2-Theta, 20,3±0,1° 2-Theta;
c) jedinični stanični parametri koji su jednaki sljedećima na -173°C:
[image]
d) isti uzorak rendgenske difrakcije na prahu (XRPD) kao za a) ili b) nakon skladištenja na 40°C i 75% RH u trajanju od najmanje tjedan dana; ili
e) isti uzorak rendgenske difrakcije na prahu (XRPD) kao za a) ili b) nakon skladištenja na 25°C i 92% RH u trajanju od 12 dana.
11. Uporaba prema patentnom zahtjevu 10, naznačena time, da je za liječenje bolesti, poremećaja ili stanja povezanog s djelovanjem androgenog receptora, pri čemu se kod navedene bolesti, poremećaja ili stanja povezanog s djelovanjem androgenog receptora, radi o raku prostate.
12. Postupak, naznačen time, da obuhvaća formuliranje kristalnog Oblika B od 4-[7-(6-cijano-5-trifluorometilpiridin-3-il)-8-okso-6-tiokso-5,7-diaza-spiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamida za oralnu primjenu terapijski učinkovite količine 4-[7-(6-cijano-5-trifluorometilpiridin-3-il)-8-okso-6-tiokso-5,7-diaza-spiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamida;
pri čemu je kristalni Oblik B naznačen time da posjeduje najmanje jedno od sljedećih:
a) isti uzorak rendgenske difrakcije praha (XRPD) kako je prikazan na Slici 2;
b) uzorak rendgenske difrakcije na prahu (XRPD) s karakterističnim vršnim vrijednostima na 12,1±0,1° 2-Theta, 16,0±0,1° 2-Theta, 16,7±0,1° 2-Theta, 20,1±0,1° 2-Theta, 20,3±0,1° 2-Theta;
c) jedinični stanični parametri koji su jednaki sljedećima na -173°C:
[image]
d) isti uzorak rendgenske difrakcije na prahu (XRPD) kao za a) ili b) nakon skladištenja na 40°C i 75% RH u trajanju od najmanje tjedan dana; ili
e) isti uzorak rendgenske difrakcije na prahu (XRPD) kao za a) ili b) nakon skladištenja na 25°C i 92% RH u trajanju od 12 dana,
i pri čemu se kristalni Oblik B od 4-[7-(6-cijano-5-trifluorometilpiridin-3-il)-8-okso-6-tiokso-5,7-diaza-spiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamida formulira u oralni oblik za doziranje.
13. Postupak prema patentnom zahtjevu 1, naznačen time, da se kristalni Oblik B od 4-[7-(6-cijano-5-trifluorometilpiridin-3-il)-8-okso-6-tiokso-5,7-diaza-spiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamida formulira u tabletu, prašak, pilulu ili kapsulu.
14. Tableta, pilula ili kapsula, naznačena time, da se dobiva putem postupka u skladu s patentnim zahtjevom 13.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261656888P | 2012-06-07 | 2012-06-07 | |
| EP19169275.5A EP3533792B1 (en) | 2012-06-07 | 2013-06-04 | Crystalline forms of an androgen receptor modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210909T1 true HRP20210909T1 (hr) | 2021-09-03 |
Family
ID=49712550
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180902TT HRP20180902T1 (hr) | 2012-06-07 | 2018-06-11 | Kristalni oblici modulatora receptora androgena |
| HRP20201387TT HRP20201387T1 (hr) | 2012-06-07 | 2020-08-31 | Kristalni oblici modulatora receptora androgena |
| HRP20210909TT HRP20210909T1 (hr) | 2012-06-07 | 2021-06-08 | Kristalni oblici modulatora androgenih receptora |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180902TT HRP20180902T1 (hr) | 2012-06-07 | 2018-06-11 | Kristalni oblici modulatora receptora androgena |
| HRP20201387TT HRP20201387T1 (hr) | 2012-06-07 | 2020-08-31 | Kristalni oblici modulatora receptora androgena |
Country Status (42)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008119015A2 (en) | 2007-03-27 | 2008-10-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| EP2385960B1 (en) | 2009-01-12 | 2020-03-11 | University Of Massachusetts Lowell | Polyisobutylene-based polyurethanes |
| KR20140103335A (ko) | 2011-12-16 | 2014-08-26 | 올레마 파마슈티컬스 인코포레이티드 | 신규한 벤조피란 화합물, 조성물 및 이의 용도 |
| EA028791B1 (ru) | 2012-06-07 | 2017-12-29 | Арагон Фармасьютикалз, Инк. | Кристаллическая форма модулятора андрогенных рецепторов |
| TWI673051B (zh) | 2012-09-11 | 2019-10-01 | 美商梅維森前列腺療法有限責任公司 | 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物 |
| BR112015006705A8 (pt) | 2012-09-26 | 2019-08-27 | Aragon Pharmaceuticals Inc | antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastático e usos destes |
| EP2922888B1 (en) | 2012-11-21 | 2021-08-18 | The University of Massachusetts | High strength polyisobutylene polyurethanes |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| JP2017525727A (ja) * | 2014-08-26 | 2017-09-07 | アスター バイオテック リミテッド ライアビリティ カンパニー | プロテインキナーゼ阻害剤 |
| PL3226842T3 (pl) | 2014-12-05 | 2021-07-12 | Aragon Pharmaceuticals, Inc. | Kompozycje przeciwnowotworowe |
| MA41107A (fr) | 2014-12-05 | 2017-10-10 | Aragon Pharmaceuticals Inc | Compositions anti-cancéreuses |
| ES2883187T3 (es) | 2014-12-05 | 2021-12-07 | Aragon Pharmaceuticals Inc | Composiciones anticancerosas |
| CA3091108A1 (en) | 2014-12-19 | 2016-06-23 | Lutron Technology Company Llc | Multi-channel lighting fixture having multiple light-emitting diode drivers |
| BR112018074965A2 (pt) | 2016-06-03 | 2019-03-12 | Aragon Pharmaceuticals, Inc. | composições anticancerígenas |
| ES2952770T3 (es) | 2016-12-13 | 2023-11-06 | Watson Lab Inc | Formas de estado sólido de apalutamida |
| WO2018165273A1 (en) | 2017-03-07 | 2018-09-13 | Cardiac Pacemakers, Inc. | Hydroboration/oxidation of allyl-terminated polyisobutylene |
| EP3668912B1 (en) | 2017-08-17 | 2021-06-30 | Cardiac Pacemakers, Inc. | Photocrosslinked polymers for enhanced durability |
| CA3079135A1 (en) | 2017-10-16 | 2019-04-25 | Arturo Molina | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| WO2019135254A1 (en) * | 2018-01-02 | 2019-07-11 | Mylan Laboratories Limited | Apalutamide polymorphs and their preparation thereof |
| CN111479596B (zh) | 2018-01-17 | 2023-04-07 | 心脏起搏器股份公司 | 封端聚异丁烯聚氨酯 |
| US20200270226A1 (en) | 2018-06-20 | 2020-08-27 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystalline forms of arn-509, preparation method and use thereof |
| WO2020049598A2 (en) | 2018-09-08 | 2020-03-12 | Cipla Limited | Apalutamide polymorphs |
| IT201900003839A1 (it) | 2019-03-15 | 2020-09-15 | Olon Spa | Sintesi di apalutamide amorfa stabile |
| WO2020234817A1 (en) * | 2019-05-21 | 2020-11-26 | Laurus Labs Limited | Polymorphic forms of apalutamide and its preparation thereof |
| IT201900010593A1 (it) * | 2019-07-01 | 2021-01-01 | Dipharma Francis Srl | Forma cristallina di un inibitore di recettori degli androgeni |
| US20220281836A1 (en) * | 2019-08-22 | 2022-09-08 | Dr. Reddy's Laboratories Limited | Process for the preparation of apalutamide |
| IT201900015974A1 (it) | 2019-09-10 | 2021-03-10 | Olon Spa | Apalutamide cristallina stabile in forma pura e processo per la sua preparazione |
| CN110590740A (zh) * | 2019-09-20 | 2019-12-20 | 武汉大学 | 一种阿帕鲁胺化合物及其药物制剂 |
| EP4208451A1 (en) | 2020-09-04 | 2023-07-12 | Synthon B.V. | Improved process for preparation of apalutamide |
| WO2023143090A1 (zh) * | 2022-01-25 | 2023-08-03 | 成都苑东生物制药股份有限公司 | 一种阿帕他胺溶剂化物新晶型及其制备方法 |
| CN115536634A (zh) * | 2022-10-17 | 2022-12-30 | 上海博悦生物科技有限公司 | 一种阿帕他胺的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| CN101032483B (zh) * | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| HUE053877T2 (hu) * | 2006-03-27 | 2021-07-28 | Univ California | Androgén receptormodulátor a prosztatarák és az androgén receptorral összefüggõ betegségek kezeléséhez |
| NZ572374A (en) | 2006-03-29 | 2011-12-22 | Univ California | Diarylthiohydantoin compounds |
| WO2008119015A2 (en) * | 2007-03-27 | 2008-10-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| CN106983749A (zh) * | 2010-02-16 | 2017-07-28 | 亚拉冈制药公司 | 雄激素受体调节剂及其用途 |
| EA028791B1 (ru) | 2012-06-07 | 2017-12-29 | Арагон Фармасьютикалз, Инк. | Кристаллическая форма модулятора андрогенных рецепторов |
| US20200270226A1 (en) | 2018-06-20 | 2020-08-27 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystalline forms of arn-509, preparation method and use thereof |
-
2013
- 2013-06-04 EA EA201492272A patent/EA028791B1/ru unknown
- 2013-06-04 NZ NZ702203A patent/NZ702203A/en unknown
- 2013-06-04 MX MX2014015005A patent/MX356754B/es active IP Right Grant
- 2013-06-04 PT PT138006812T patent/PT2858985T/pt unknown
- 2013-06-04 PT PT191692755T patent/PT3533792T/pt unknown
- 2013-06-04 PE PE2014002383A patent/PE20150631A1/es active IP Right Grant
- 2013-06-04 LT LTEP13800681.2T patent/LT2858985T/lt unknown
- 2013-06-04 EP EP21171579.2A patent/EP3922629A1/en active Pending
- 2013-06-04 ES ES19169275T patent/ES2875932T3/es active Active
- 2013-06-04 TR TR2018/08939T patent/TR201808939T4/tr unknown
- 2013-06-04 SI SI201331010T patent/SI2858985T1/sl unknown
- 2013-06-04 EP EP13800681.2A patent/EP2858985B1/en active Active
- 2013-06-04 ES ES18157435T patent/ES2809738T3/es active Active
- 2013-06-04 RS RS20210739A patent/RS61988B1/sr unknown
- 2013-06-04 CA CA2875767A patent/CA2875767C/en active Active
- 2013-06-04 RS RS20180680A patent/RS57370B1/sr unknown
- 2013-06-04 CA CA3114726A patent/CA3114726A1/en active Pending
- 2013-06-04 CR CR20190331A patent/CR20190331A/es unknown
- 2013-06-04 DK DK13800681.2T patent/DK2858985T3/en active
- 2013-06-04 DK DK18157435.1T patent/DK3348553T3/da active
- 2013-06-04 LT LTEP19169275.5T patent/LT3533792T/lt unknown
- 2013-06-04 HU HUE19169275A patent/HUE054595T2/hu unknown
- 2013-06-04 EA EA201791592A patent/EA033956B1/ru unknown
- 2013-06-04 NZ NZ717683A patent/NZ717683A/en unknown
- 2013-06-04 RS RS20200913A patent/RS60617B1/sr unknown
- 2013-06-04 KR KR1020197033592A patent/KR102195916B1/ko active IP Right Grant
- 2013-06-04 EP EP18157435.1A patent/EP3348553B1/en active Active
- 2013-06-04 AU AU2013271751A patent/AU2013271751B2/en active Active
- 2013-06-04 HU HUE13800681A patent/HUE038082T2/hu unknown
- 2013-06-04 PT PT181574351T patent/PT3348553T/pt unknown
- 2013-06-04 SG SG10201610248SA patent/SG10201610248SA/en unknown
- 2013-06-04 SG SG10201610249TA patent/SG10201610249TA/en unknown
- 2013-06-04 ME MEP-2020-163A patent/ME03815B/me unknown
- 2013-06-04 PL PL19169275T patent/PL3533792T3/pl unknown
- 2013-06-04 SI SI201331894T patent/SI3533792T1/sl unknown
- 2013-06-04 UA UAA201702779A patent/UA123142C2/uk unknown
- 2013-06-04 ES ES13800681.2T patent/ES2670683T3/es active Active
- 2013-06-04 MY MYPI2014703627A patent/MY187500A/en unknown
- 2013-06-04 CN CN201610202980.2A patent/CN105693692A/zh active Pending
- 2013-06-04 CN CN201380041652.3A patent/CN104619692A/zh active Pending
- 2013-06-04 SI SI201331788T patent/SI3348553T1/sl unknown
- 2013-06-04 IN IN10084DEN2014 patent/IN2014DN10084A/en unknown
- 2013-06-04 TW TW102119817A patent/TWI532732B/zh active
- 2013-06-04 KR KR1020157000266A patent/KR102062024B1/ko active IP Right Grant
- 2013-06-04 LT LTEP18157435.1T patent/LT3348553T/lt unknown
- 2013-06-04 BR BR112014030678A patent/BR112014030678A2/pt not_active Application Discontinuation
- 2013-06-04 SG SG11201408140QA patent/SG11201408140QA/en unknown
- 2013-06-04 JP JP2015516121A patent/JP6182209B2/ja active Active
- 2013-06-04 EA EA201992010A patent/EA201992010A1/ru unknown
- 2013-06-04 PL PL13800681T patent/PL2858985T3/pl unknown
- 2013-06-04 CA CA3008345A patent/CA3008345C/en active Active
- 2013-06-04 UA UAA201500086A patent/UA115665C2/uk unknown
- 2013-06-04 PL PL18157435T patent/PL3348553T3/pl unknown
- 2013-06-04 PE PE2019002096A patent/PE20200725A1/es unknown
- 2013-06-04 ME MEP-2018-158A patent/ME03081B/me unknown
- 2013-06-04 HU HUE18157435A patent/HUE050357T2/hu unknown
- 2013-06-04 DK DK19169275.5T patent/DK3533792T3/da active
- 2013-06-04 CN CN202110417935.XA patent/CN113135892A/zh active Pending
- 2013-06-04 US US14/406,520 patent/US9481663B2/en active Active
- 2013-06-04 EP EP19169275.5A patent/EP3533792B1/en active Active
- 2013-06-04 WO PCT/US2013/044116 patent/WO2013184681A1/en active Application Filing
- 2013-06-04 CA CA3055660A patent/CA3055660A1/en not_active Abandoned
-
2014
- 2014-12-01 CR CR20140549A patent/CR20140549A/es unknown
- 2014-12-04 NI NI201400142A patent/NI201400142A/es unknown
- 2014-12-04 IL IL236055A patent/IL236055A0/en unknown
- 2014-12-04 PH PH12014502714A patent/PH12014502714B1/en unknown
- 2014-12-05 GT GT201400283A patent/GT201400283A/es unknown
- 2014-12-05 CL CL2014003331A patent/CL2014003331A1/es unknown
- 2014-12-05 EC ECIEPI201430098A patent/ECSP14030098A/es unknown
- 2014-12-09 CO CO14270612A patent/CO7240407A2/es unknown
-
2015
- 2015-01-06 ZA ZA2015/00076A patent/ZA201500076B/en unknown
- 2015-11-11 HK HK15111086.5A patent/HK1210175A1/xx unknown
-
2016
- 2016-07-26 PH PH12016501470A patent/PH12016501470A1/en unknown
- 2016-09-12 US US15/262,522 patent/US9994545B2/en active Active
- 2016-12-19 HK HK16114389A patent/HK1226066A1/zh unknown
-
2017
- 2017-01-17 AU AU2017200298A patent/AU2017200298B2/en active Active
- 2017-02-15 JP JP2017025746A patent/JP6345821B2/ja active Active
- 2017-12-22 AU AU2017279807A patent/AU2017279807B2/en active Active
-
2018
- 2018-05-09 US US15/975,449 patent/US10308630B2/en active Active
- 2018-05-23 JP JP2018098638A patent/JP2018141009A/ja active Pending
- 2018-05-31 IL IL259738A patent/IL259738B/en active IP Right Grant
- 2018-06-11 HR HRP20180902TT patent/HRP20180902T1/hr unknown
- 2018-07-06 CY CY20181100712T patent/CY1120393T1/el unknown
-
2019
- 2019-04-15 US US16/384,002 patent/US10526310B2/en active Active
- 2019-06-24 IL IL267608A patent/IL267608A/en unknown
- 2019-07-10 US US16/507,780 patent/US10556882B2/en active Active
- 2019-12-11 US US16/710,785 patent/US10766875B2/en active Active
-
2020
- 2020-06-15 IL IL275413A patent/IL275413A/en unknown
- 2020-07-29 US US16/942,069 patent/US10934271B2/en active Active
- 2020-08-31 HR HRP20201387TT patent/HRP20201387T1/hr unknown
- 2020-09-23 CY CY20201100901T patent/CY1123427T1/el unknown
-
2021
- 2021-01-26 US US17/158,806 patent/US20210163441A1/en active Pending
- 2021-06-08 HR HRP20210909TT patent/HRP20210909T1/hr unknown
- 2021-07-02 CY CY20211100595T patent/CY1124831T1/el unknown
- 2021-11-02 NO NO2021046C patent/NO2021046I1/no unknown
- 2021-11-03 FR FR21C1050C patent/FR21C1050I2/fr active Active
- 2021-11-03 LT LTPA2021525C patent/LTPA2021525I1/lt unknown
- 2021-11-04 HU HUS2100047C patent/HUS2100047I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210909T1 (hr) | Kristalni oblici modulatora androgenih receptora | |
| HRP20200991T1 (hr) | Modulator androgenog receptora u kombinaciji s abirateron acetatom i prednizonom za liječenje karcinoma prostate | |
| JP2011068653A5 (hr) | ||
| HRP20171201T1 (hr) | Postupak kristalizacije i biodostupnost | |
| HRP20210144T1 (hr) | Kompozicije koje sadrže inhibitor lizin specifične demetilaze-1 koje imaju pirimidinski prsten i njihova primjena u liječenju raka | |
| MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
| HRP20171755T1 (hr) | Postupak kristalizacije i biološka raspoloživost | |
| IL258732A (en) | Salts and their benzene and polymorphs | |
| HRP20201343T1 (hr) | Kristalni oblici 5-kloro-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoksi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidin-2,4-diamina | |
| RU2007147427A (ru) | Кристаллические и другие формы солей, образованных из молочной кислоты и 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она | |
| HRP20210681T1 (hr) | Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida | |
| HRP20140648T1 (hr) | Nalmefen hidroklorid dihidrat | |
| MX2019009777A (es) | Sistemas y metodos para la fabricacion de tabletas, que incluyen tabletas farmaceuticas. | |
| CN103391924A (zh) | 抗病毒的缩合杂环化合物 | |
| JP2009149648A5 (hr) | ||
| HRP20171587T1 (hr) | Spojevi, pripravci i postupci pogodni za mobilizaciju kolesterola | |
| JP2015038135A5 (hr) | ||
| US20100189781A1 (en) | Alkoxyalkyl s-prenylthiosalicylates for treatment of cancer | |
| NZ628993A (en) | Pharmaceutical formulations comprising ccr3 antagonists | |
| HRP20210667T1 (hr) | Kristalni oblici antagonista androgenog receptora, postupak pripreme i njihova upotreba | |
| HRP20201736T1 (hr) | Postupak liječenja diskinezije | |
| SI3029039T1 (en) | Pharmaceutical formulations containing crystalline forms of (R) -7-chloro-N- (quinuclidin-3-yl) benzo (b) thiophene-2-carboxamide hydrochloride monohydrate | |
| PH12014501408A1 (en) | Immediate release multi unit pellet system | |
| EA200901146A1 (ru) | Твердые лекарственные формы, содержащие алискирен и его фармацевтически приемлемые соли | |
| JP2015522037A5 (hr) |